Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Tesla Raises Cybertruck Prices by $5,000 in US 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Add as a preferred source on Google
CAMBRIDGE, Mass., May 02, 2018 -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report first quarter 2018 financial results on Wednesday, May 9, 2018. Jounce Therapeutics' management team will host a live conference call and webcast to discuss these results and provide a corporate update at 8:00 a.m. ET.
Conference Call and Webcast
To access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 3760478. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at www.jouncetx.com. The webcast will be archived and made available for replay on the company’s website approximately two hours after the call and will be available for 30 days thereafter.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in the Phase 2 portion of the Phase 1/2 ICONIC trial. For more information, please visit www.jouncetx.com.
Investor and Media Contact:
Komal Joshi
Jounce Therapeutics, Inc.
(857) 320-2523
[email protected]
